References
- American Cancer Society. Cancer Facts & Figures 2016 [Internet]. [cited 2016Oct 16]. Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf.
- American Cancer Society. Global cancer facts & Figures 3rd edition [Internet]. (2012). Available from: http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-044738.pdf.
- NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet (London, England) [Internet]. 2014;383(9928):1561–1571. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4022989&tool=pmcentrez&rendertype=abstract
- Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med [Internet]. 1990;323(14):940–945. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2169587
- Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol [Internet]. 2010;28(13):2181–2190. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20351327
- O’Rourke N, Roqué I, Figuls M, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev [Internet]. 2010;(6):CD002140. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20556756
- Thomas M, Rübe C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol [Internet]. 2008;9(7):636–648. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18583190
- Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (London, England) [Internet]. 2009;374(9687):379–386. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4407808&tool=pmcentrez&rendertype=abstract
- Stupp R, Mayer M, Kann R, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol [Internet]. 2009;10(8):785–793. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19604722
- Pless M, Stupp R, Ris H-B, et al. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. Lancet (London, England) [Internet]. 2015;386(9998):1049–1056. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26275735
- Katakami N, Tada H, Mitsudomi T, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer [Internet]. 2012;118(24):6126–6135. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22674529
- Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol [Internet]. 1995;13(8):1880–1892. Available from: Available from: http://www.ncbi.nlm.nih.gov/pubmed/7636530
- Eberhardt WEE, Pottgen C, Gauler TC, et al. Phase III study of surgery versus definitive concurrent chemoradiotherapy boost in patients with resectable stage IIIA(N2) and selected IIIB non-small-cell lung cancer after induction chemotherapy and concurrent chemoradiotherapy (ESPATUE). J Clin Oncol [Internet]. 2015;33(35):4194–4201. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26527789
- Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am [Internet]. 1987;67(5):1037–1049. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3629423
- Watanabe Y, Shimizu J, Oda M, et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg [Internet]. 1991;51(2):253–261. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1846524
- Naruke T, Goya T, Tsuchiya R, et al. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg [Internet]. 1988;46(6):603–610. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2848463
- Mountain CF. Expanded possibilities for surgical treatment of lung cancer. Survival in stage IIIa disease. Chest [Internet]. 1990;97(5):1045–1051. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2158877
- Rosell R, Gómez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med [Internet]. 1994;330(3):153–158. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8043059
- Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 non-small cell lung cancer: analysis of the literature. Lung Cancer [Internet]. 1998;19(1):3–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9493135
- Cybulsky IJ, Lanza LA, Ryan MB, et al. Prognostic significance of computed tomography in resected N2 lung cancer. Ann Thorac Surg [Internet]. 1992;54(3):533–537. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1324657
- Vansteenkiste JF, De Leyn PR, Deneffe GJ, et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg [Internet] 1997;63(5):1441–1450. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9146340
- Pearson FG, DeLarue NC, Ilves R, et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg [Internet]. 1982;83(1):1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7054602
- Casali C, Stefani A, Natali P, et al. Prognostic factors in surgically resected N2 non-small cell lung cancer: the importance of patterns of mediastinal lymph nodes metastases. Eur J Cardiothorac Surg [Internet]. 2005;28(1):33–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15953734
- Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol [Internet]. 2000;18(16):2981–2989. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10944131
- Baik CS, Vallières E, Martins RG. The role of chemotherapy in the management of stage IIIA non-small cell lung cancer. Am Soc Clin Oncol Educ Book [Internet]. 2013;320–325. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23714535
- Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest [Internet]. 2013;143(5 Suppl):e314S–40S. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23649445
- Douillard J-Y, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol [Internet]. 2006;7(9):719–727. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16945766
- Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst [Internet]. 2003;95(19):1453–1461. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14519751
- Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage I-IIIA non-small cell lung cancer. Br J Cancer [Internet]. 2006;95(7):817–821. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16969350
- Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med [Internet]. 2004;350(4):351–360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14736927
- Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med [Internet]. 2004;350(17):1713–1721. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15102997
- Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (London, England) [Internet]. 2010;375(9722):1267–1277. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2853682&tool=pmcentrez&rendertype=abstract
- Artal Cortés Á, Calera Urquizu L, Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res [Internet]. 2015;4(2):191–197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25870801
- Le Chevalier T. Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol [Internet]. 2010;21(Suppl 7):vii196–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20943614
- Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol [Internet]. 2002;20(1):247–253. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11773176
- Mattson KV, Abratt RP, Ten Velde G, et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol [Internet]. 2003;14(1):116–122. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12488303
- Gilligan D, Nicolson M, Smith I, et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet (London, England) [Internet]. 2007;369(9577):1929–1937. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17544497
- Pisters KMW, Vallieres E, Crowley JJ, et al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, phase III trial. J Clin Oncol [Internet]. 2010;28(11):1843–1849. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2860367&tool=pmcentrez&rendertype=abstract
- Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol [Internet]. 2012;30(2):172–178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22124104
- Felip E, Rosell R, Maestre JA, et al. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol [Internet]. 2010;28(19):3138–3145. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20516435
- Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg [Internet]. 2003;125(2):254–260. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12579093
- Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst [Internet]. 1994;86(9):673–680. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8158698
- Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer [Internet]. 1998;21(1):1–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9792048
- Girard N, Mornex F, Douillard J-Y, et al. Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? mature results of the randomized IFCT-0101 phase II trial. Lung Cancer [Internet]. 2010;69(1):86–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19879013
- Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol [Internet]. 1992;10(8):1237–1244. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1321893
- Deutsch M, Crawford J, Leopold K, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer [Internet]. 1994;74(4):1243–1252. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8055445
- Higgins K, Chino JP, Marks LB, et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys [Internet]. 2009;75(5):1462–1467. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19467798
- Pezzetta E, Stupp R, Zouhair A, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg [Internet]. 2005;27(6):1092–1098. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15896624
- Bharadwaj SC, Vallières E, Wilshire CL, et al. Higher versus standard preoperative radiation in the trimodality treatment of stage IIIa lung cancer. Ann Thorac Surg [Internet] [ discussion 213–4]. 2015;100(1):207–213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26047995
- Toyooka S, Kiura K, Takemoto M, et al. Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg [Internet]. 2012;14(5):565–569. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3329306&tool=pmcentrez&rendertype=abstract
- Toyooka S, Kiura K, Shien K, et al. Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis. Interact Cardiovasc Thorac Surg [Internet]. 2012;15(6):954–960. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3501315&tool=pmcentrez&rendertype=abstract
- Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol [Internet]. 1998;16(2):622–634. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9469351
- Mikell JL, Gillespie TW, Hall WA, et al. Postoperative radiotherapy is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the National Cancer Data Base. J Thorac Oncol [Internet]. 2015;10(3):462–471. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4336617&tool=pmcentrez&rendertype=abstract
- Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol [Internet]. 2006;24(19):2998–3006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16769986
- Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and Leukemia Group B. J Clin Oncol [Internet]. 2007;25(13):1698–1704. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17404369
- Shah AA, Berry MF, Tzao C, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg [Internet]. 2012;93(6):1807–1812. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22632486
- Xu Y-P, Li B, Xu X-L, et al. Is there a survival benefit in patients with stage IIIA (N2) non-small cell lung cancer receiving neoadjuvant chemotherapy and/or radiotherapy prior to surgical resection: a systematic review and meta-analysis. Medicine (Baltimore) [Internet]. 2015;94(23):e879. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4616485&tool=pmcentrez&rendertype=abstract
- Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology G. Int J Radiat Oncol Biol Phys [Internet]. 2002;54(2):365–369. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12243809
- Van Meerbeeck JP, Kramer GWPM, Van Schil PEY, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst [Internet]. 2007;99(6):442–450. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17374834
- Eberhardt WEE, Stamatis G, Stuschke M. Surgery in stage III non-small-cell lung cancer. Lancet (London, England) [Internet]. 2009;374(9687):359–360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19632715
- Jeremić B. Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer [Internet]. 2015;16(2):80–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25450877
- Kumar P, Herndon J, Langer M, et al. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer [Internet]. 1996;77(11):2393–2399. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8635112
- Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol [Internet]. 1997;15(2):712–722. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9053497
- Marulli G, Verderi E, Zuin A, et al. Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection. Interact Cardiovasc Thorac Surg [Internet]. [ discussion 262]. 2014;19(2):256–262. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24824495
- Zhong W, Yang X, Yan H, et al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status. J Hematol Oncol [Internet]. 2015;8(54). Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4455050&tool=pmcentrez&rendertype=abstract
- Chaft JE, Dunphy M, Naidoo J, et al. Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non-small cell lung cancers: the NEOSCAN trial. J Thorac Oncol [Internet]. 2016;11(4):537–544. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26724474
- Pottgen C, Gauler T, Bellendorf A, et al. Standardized uptake decrease on [18F]-fluorodeoxyglucose positron emission tomography after neoadjuvant chemotherapy is a prognostic classifier for long-term outcome after multimodality treatment: secondary analysis of a randomized trial for resectable st. J Clin Oncol [Internet]. 2016;34(21). Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.65.5167
- Falcoz P-E, Puyraveau M, Rivera C, et al. The impact of hospital and surgeon volume on the 30-day mortality of lung cancer surgery: a nation-based reappraisal. J Thorac Cardiovasc Surg [Internet] [ discussion 848]. 2014;148(3):841–848. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24534677
- De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage II. J Clin Oncol [Internet]. 2006;24(21):3333–3339. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16849747
- Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer [Internet]. 2002;35(2):179–187. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11804691
- Marra A, Hillejan L, Fechner S, et al. Remediastinoscopy in restaging of lung cancer after induction therapy. J Thorac Cardiovasc Surg [Internet]. 2008;135(4):843–849. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18374765
- Call S, Rami-Porta R, Obiols C, et al. Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures. Eur J Cardiothorac Surg [Internet]. 2011;39(6):1022–1027. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21112217
- De Waele M, Serra-Mitjans M, Hendriks J, et al. Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients. Eur J Cardiothorac Surg [Internet]. 2008;33(5):824–828. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18342528
- de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol [Internet]. 2010;5(3):389–398. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20186025
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med [Internet]. 2015;373(17):1627–1639. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26412456
- Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet [Internet]. 2015;387(10027):1540–1550. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26712084
- Munagala R, Aqil F, Gupta RC. Exosomal miRNAs as biomarkers of recurrent lung cancer. Tumour Biol [Internet]. 2016;37:10703–10714. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26867772
- Carvalho S, Troost EGC, Bons J, et al. Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer – A survival model with external validation. Radiother Oncol [Internet]. 2016. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27139126
- Hu Q, Xiao P, Li J, et al. A retrospective analysis of serum tumor markers found in non-small cell lung cancer. J Cancer Res Ther [Internet]. 2016;12(1):117–120. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27072222
- Fiala O, Pesek M, Finek J, et al. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res [Internet]. 2016;36(1):461–466. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26722082
- Sun Z, Chen X, Wang G, et al. Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology. Biomark Res [Internet]. 2016;4(11). Available from: http://www.ncbi.nlm.nih.gov/pubmed/27252855
- Sacher AG, Le LW, Lara-Guerra H, et al. A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer. Oncotarget [Internet]. (2016; Available from: http://www.ncbi.nlm.nih.gov/pubmed/27028852